DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

The recorded presentation will be available on the Investors section of the Company’s website at https://www.diamedica.com/investors/events-presentations beginning Thursday, April 29th.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, visit www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005062/en/

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
[email protected]

For Investor Inquiries:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
[email protected]

Source: DiaMedica Therapeutics Inc.

You May Also Be Interested In

• Future Health Convenes Global Health Leaders at UNGA to Advance Health System Transformation at Scale
• b4.bet Appoints Former World Cup Winner as Brand Ambassador for Malaysia as the European Club Season Gets Underway
• SUI Price Prediction: SUI Rallies 45% This Month as Remittix Heads Toward Its $0.46 Final Stage—Which Payment Crypto Wins?